

numares AG Opens Singapore Subsidiary to Expand Its Diagnostic System into Asia

- *Company's AXINON[®] system and diagnostic tests enable laboratories to perform precision diagnostics using metabolomics*
- *Richard Yap, experienced medical technology executive in Asian markets, will head the office, numares Singapore Pte. Ltd., as managing director.*

REGENSBURG, Germany, 08 December, 2016 – numares AG, a fast-growing innovative diagnostics company focused on the development and use of metabolomics networks in high-throughput test systems for clinical diagnostics and life science research, today announced its expansion into the Asian diagnostic market with the opening of its Asian subsidiary in Singapore. Richard Yap, a medical technology marketing executive with extensive experience in Asia, will head the Singapore office.

From its regional base in Singapore, numares targets the growing demand for innovative diagnostic solutions in the emerging Asian countries. Specifically, numares plans to introduce to the Asian market, *AXINON[®] lipoFIT[®]*, the Company's first commercialized *in vitro* diagnostic test system, which analyzes lipoprotein particles that are important risk factors for atherosclerotic disease. The *lipoFIT[®]* test helps physicians initiate measures to reduce the risk of stroke and myocardial infarction.

numares' next-generation of diagnostic test systems, which evaluate metabolomics networks, are designed to be easy-to-use, high-throughput and cost-efficient. The numares *AXINON[®]* system and specific testing software decipher metabolic networks by evaluating NMR (nuclear magnetic resonance) spectra rather than identify the presence or specific amount of a single biomarker. This will support physicians to initiate earlier medical interventions, more efficient determination of appropriate drug therapies and better diagnoses based on the patient's current metabolic status. The tests are software-based rather than chemistry-based (i.e. no specialized reagents to process antibodies, proteins or nucleic acids) so are affordable for laboratories and patients.

Richard Yap, recently appointed as a managing director, will be responsible for the development of the Asian market. The 52-year-old engineer has more than 25 years of experience in the distribution of medical products in the Asian Pacific region. He was the regional managing director for OrbusNeich, a leading provider of treatment solutions for coronary heart diseases, and most recently advised medical technology companies on entering the Asian market.

"Our new office in Singapore, will enable us to strategically position ourselves in the Asian diagnostic market so that we meet its growing demand for innovative diagnostic solutions,"

said Titus Kaletta, chief operating officer of numares AG. "The Asia Pacific region is the fastest growing diagnostic market in the world. Richard, with his extensive experience launching and marketing technologically advanced medical products in this region, will be an invaluable part of our commercial team. We are delighted that he has joined numares."

Mr. Yap added, "I am looking forward to this new assignment. Exploiting metabolomic networks for diagnostics with software-based affordable technology has enormous potential, not least when it comes to providing increasing value while confronting cost pressures in health care worldwide. Together with numares' international team, I would like to support the company in developing an important future market and thus to continue the international growth course of numares."

A photo of Richard Yap is available upon request.

About numares

numares AG is a fast-growing innovative diagnostics company developing and marketing software-based test systems for high-throughput use in clinical diagnostics and life science research. The AXINON[®] IVD system and its diagnostic tests employ nuclear magnetic resonance (NMR) spectroscopy creating a numeric spectrum to evaluate metabolomic networks. The output from these analyses provide physicians valuable information on the disease status of patients. numares developed its proprietary *Magnetic Group Signaling*[®] (MGS[®]) technology to enable NMR for highly standardized and rapid throughput testing forming a cost-efficient new solution for diagnostic purposes. The metabolomics tests address unmet medical needs in the indication fields of cardiovascular diseases, nephrology, oncology and neurology, shaping another important pillar in precision medicine.

More information can be found at www.numares.com.

For further information please contact:

numares AG
Dipl.-Biol. Christiane Proll, MBA
Tel.: +49 941 2809 49-14
E-Mail: christiane.proll@numares.com

IRA WÜLFING KOMMUNIKATION GmbH
Dr. Reinhard Saller
Tel.: +49 89 2000 30-38
E-Mail: reinhard.saller@wuelfing-kommunikation.de

U.S.A.
The Ruth Group
Investors:
Robert Flamm, Ph.D.
Tel.: 1-646-536-7017
E-Mail: rflamm@theruthgroup.com



Media:
Christopher Hippolyte
Tel.: 1-646-536-7023
E-Mail: chippolyte@theruthgroup.com